August 27, 2014: UBS analyst Andrew Peters noted that Achillion was a potential takeover target, which caused the company’s stock to jump to a 52-week high of $11.52 in Monday’s trading.
August 27, 2014: Vaccinogen plans to move to Baltimore within the next six months. Vaccinogen intends to increase its headcount by more than 300%.
August 27, 2014: With the stock market rife with rumors and speculation about mergers and acquisitions in the biotech space, Novo Nordisk CEO Lars Sorensen said, “We have no plans whatsoever in buying anything larger than things that we can finance through our own cash flows.”
August 27, 2014: These have been good times for the biotech industry. According to Ernst & Young, industry revenue jumped 10 percent last year to almost $100 billion while R&D spending climbed 14 percent (and a very strong 20 percent in the U.S.)—a trend that looks likely to continue into this year.